A Phase 1 interventional study of Survodutide formulation A and Survodutide formulation B2 in Healthy and Obesity, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
The goal of this study is to find out whether different formulations of survodutide given by different delivery methods is taken up in the body in a similar way.
Participants visit the study site regularly. During study visits, the doctors collect information about participants' health. To assess the study endpoints, participants regularly have blood samples taken.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 56 is below the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Survodutide formulation A = Reference treatment Survodutide formulation B2 = Test treatment
Combination Product: Survodutide formulation A · Combination Product: Survodutide formulation B2
Survodutide formulation A = Reference treatment Survodutide formulation B2 = Test treatment
Combination Product: Survodutide formulation A · Combination Product: Survodutide formulation B2
Pre-filled syringe
Also known as: BI 456906
Pre-filled pen
Also known as: BI 456906
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Time frame: Up to Day 22
Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: Up to Day 22
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: Up to Day 22
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boehringer Ingelheim